Showing 7 of 7 recruiting trials for “Post-transplant lymphoproliferative disease”
Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell Transplantation
Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)
👨⚕️ Neha Mehta-Shah, M.D., Washington University School of Medicine📍 1 site📅 Started Oct 2023View details ↗
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
👨⚕️ Stephen D. Smith, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Aug 2023View details ↗
Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
👨⚕️ Timothy J Voorhees, MD, MSCR, Ohio State University Comprehensive Cancer Center📍 3 sites📅 Started Mar 2023View details ↗
Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →